source
- Moderna sticks to 10% revenue growth goal despite Phase 3 norovirus vaccine missModerna said it will continue to aim for up to 10% revenue growth this year, even though its experimental norovirus vaccine did not achieve statistical significance in a Phase 3 interim analysis.…
- Sanofi CEO pledges deeper review of late-stage pipeline before Phase 3 movesSanofi's new chief executive, Belén Garijo, announced that the company will examine its late-stage pipeline more closely. The goal is to ensure that data from Phase 2 (or Phase 1b, depending on th…